Trabectedin is a promising antitumour agent for synovial sarcoma
| العنوان: | Trabectedin is a promising antitumour agent for synovial sarcoma |
|---|---|
| المؤلفون: | Satoru Sasagawa, Akira Myoui, Takaaki Nakai, Shutaro Yamada, Kenichiro Hamada, Satoshi Takenaka, Nobuhito Araki, Norifumi Naka, Hidetatsu Outani, Yoshinori Imura, Kazuyuki Itoh, Hirohiko Yasui, Hideki Yoshikawa |
| المصدر: | Journal of Chemotherapy. 28:417-424 |
| بيانات النشر: | Informa UK Limited, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Pathology, Apoptosis, Mice, 0302 clinical medicine, Tetrahydroisoquinolines, Cytotoxic T cell, Pharmacology (medical), Trabectedin, BRCA1 Protein, Cell Cycle, Nuclear Proteins, Middle Aged, Flow Cytometry, Immunohistochemistry, Synovial sarcoma, DNA-Binding Proteins, Infectious Diseases, Oncology, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Blotting, Western, Antineoplastic Agents, Dioxoles, Sarcoma, Synovial, Young Adult, 03 medical and health sciences, In vivo, Cell Line, Tumor, Biomarkers, Tumor, medicine, Animals, Humans, Cell Proliferation, Pharmacology, business.industry, Endonucleases, medicine.disease, Xenograft Model Antitumor Assays, In vitro, 030104 developmental biology, Cell culture, Cancer research, ERCC1, business, Transcription Factors |
| الوصف: | Synovial sarcoma (SS) is an aggressive soft tissue tumour with poor prognosis. Using five human SS cell lines, we examined the cytotoxic effects of trabectedin (ET-743; Yondelis(®)), a novel marine natural product, which was approved in Europe for the treatment of soft tissue sarcomas (STS). The significant growth inhibitory effects were observed in all SS cell lines below nanomolar concentration of trabectedin. Furthermore, trabectedin significantly suppressed the tumour growth in xenograft models. Flow cytometer analysis in vitro and immunohistochemical analysis in vivo revealed its effect of cell cycle inhibition and apoptosis induction. We also examined the expression of ERCC1, 5 and BRCA1 in SS cell lines and clinical samples, and majority of them showed highly trabectedin-sensitive pattern as previously reported in other cancers. Our preclinical data indicated that trabectedin could be a promising therapeutic option for patients with SS. |
| تدمد: | 1973-9478 1120-009X |
| DOI: | 10.1080/1120009x.2015.1133013 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603c2f1031c6e891a5c397b7a700caef https://doi.org/10.1080/1120009x.2015.1133013 |
| رقم الانضمام: | edsair.doi.dedup.....603c2f1031c6e891a5c397b7a700caef |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19739478 1120009X |
|---|---|
| DOI: | 10.1080/1120009x.2015.1133013 |